FIRST STEPS IN THE DEVELOPMENT AND PRODUCTION OF CLINICAL REFERENCE MATERIAL FOR AMYLOID-B1-42 IN HUMAN CEREBROSPINAL FLUID

were determined using a Taq-Man assay. A total of 35 PFAA profiles were measured by liquid chromatography-mass spectrometry (LCMS). The PFAA profiles were also compared with ageand gender-matched healthy control subjects (HC, n 1⁄4 36) who had undergone a comprehensive health screening.Results: Several PFAAs have shown significant changes between patients with AD and cognitively normal subjects as well as ageand gendermatched healthy subjects. Neither age at onset, MMSE score, nor APOE genotype affects the PFAA profiles significantly in patients with AD. The area under the curve (AUC) of receiver operating characteristic (ROC) curve by a certain PFAA was found to be 0.86, suggesting a high discriminating power of PFAA to make a diagnosis of AD. Conclusions: Our results suggest that PFAA profile could be a potential blood-based biomarker for AD. We will discuss the implications of our findings for the development of screening tool and companion diagnostic test for patients with AD.